Major Chinese vaccines group eyes Riboxx adjuvant
This article was originally published in Scrip
Executive Summary
In another sign that China's pharma sector is actively seeking foreign know-how in its quest to improve innovation, the China National Biotec Group (CNBG) has linked up with the private German firm Riboxx Pharmaceuticals in a technology assessment agreement.